MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary
Less than 1 min read
MacroGenics reported results for the 2026 quarter with revenue of $32.83M and diluted EPS of $0.31, driven by milestone and royalty receipts that turned a prior-year loss into net income of $19.52M — a meaningful improvement versus the comparable 2025 quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $32.83M | $6.87M | 378% |
| Net income² | $19.52M | ($36.25M) | 153.8% |
| Diluted EPS³ | $0.31 | ($0.57) | 154.4% |
¹ Reported as “Total revenues”. ² Reported as “Net income (loss)”. ³ Reported as “Net income (loss) per share - diluted”.
Business Highlights
- Revenue growth was largely driven by a $24.5M milestone payment related to TZIELD and increased ZYNYZ royalty income, boosting both Q2 and first-half results.
- MacroGenics completed the sale of its CDMO operations to Bora, exiting contract manufacturing to concentrate on R&D and its clinical pipeline; the transaction generated $119.6M in net proceeds (July 2026) and the company expects additional partner payments that extend its cash runway through 2028.
- Pipeline progress includes advancement of three TOP1i ADC candidates (MGC026, MGC028, MGC030) and the PD-1/CTLA-4 bispecific lorigerlimab; Gilead has exercised an option on a research program.
- Management is implementing cost-reduction measures, reducing G&A and reprioritizing R&D spend to focus on clinical-stage assets.
Original SEC Filing: MACROGENICS INC [ MGNX ] - 10-Q - Aug. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.